2 not yet recruiting, 2 recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Cutaneous Lupus Erythematosus (CLE): new trials by email Literature Review of Cutaneous Lupus Erythematosus (CLE) trials Research Report on Cutaneous Lupus Erythematosus (CLE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Enpatoran - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Not yet recruiting | EMD Serono Research & Development Institute, Inc. | 404 | 2026-10-15 | 2026-09-25 |
| Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2 / Phase 3 | Recruiting | Beeline Medicines Corporation | 390 | 2026-10-01 | 2026-10-29 |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Enpatoran, Placebo, Standard of care (SoC) - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 202 | 2026-03-10 | 2026-10-06 |
| Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus Lenalidomide, Methotrexate (MTX) - Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 122 | 2025-10-01 | 2025-05-11 |
Lupus Erythematosus, Cutaneous (4) · Lupus Erythematosus, Discoid (3) · Lupus Erythematosus, Systemic (3)
Connective Tissue Diseases (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Autoimmune Diseases (3) · Immune System Diseases (3)
Lenalidomide (1) · Methotrexate (1) · Standard of Care (1)
EMD Serono Research & Development Institute, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Beeline Medicines Corporation (1)
United States (3) · Germany (2) · Australia (1) · Brazil (1) · Bulgaria (1) · France (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Romania (1) · Slovakia (1) · South Korea (1) · Spain (1) · Switzerland (1)
2025 (1)